The drug loading capacity and controlled drug release property of beta-tricalcium phosphate/rifampicin drug delivery systems constructed by different solution adsorption methods

doi:10.3969/j.issn.2095-4344.0983

Abstract

Abstract:

BACKGROUND: The drug delivery systems are commonly constructed by vacuum adsorption (VA), dynamic adsorption (DA) and static adsorption. Up to now, there is still no published studies that systematically evaluate the drug loading capacity and controlled drug release property of porous β-tricalcium phosphate (β-TCP) scaffolds loading rifampicin (RFP) constructed by these three solution adsorption methods.

OBJECTIVE: To investigate the drug loading capacity and controlled drug release property of porous β-TCP scaffolds loading RFP constructed by these three solution adsorption methods.

METHODS: The β-TCP/RFP drug delivery systems were constructed by VA, DA and SA, respectively. The mechanical strength of β-TCP, drug loading capacity and controlled drug release property of the three different drug delivery systems were analyzed.

RESULTS AND CONCLUSION: (1) There were no differences in the mechanical strength of β-TCP from VA-DDS, DA-DDS and SA-DDS (P > 0.05). The mechanical strength of β-TCP in three DDS groups was not significantly different from that of unloading β-TCP (P > 0.05). (2) The in vitro drug loading testing indicated that the unit mass of RFP in VA-DDS [(1.02±0.16) mg/g] was significantly higher than that in SA-DDS [(0.79±0.12) mg/g] or DA-DDS [(0.89±0.13) mg/g] (P < 0.05). (3) The in vitro release study showed an initial burst release of RFP in the three different DDSs within the first 12 hours and after 84 hours. At 84 hours, the cumulative release of RFP from VA-DDS, DA-DDS and SA-DDS was up to (66.82±5.16)%, (79.49±3.50)% and (91.30±5.86%), respectively (P < 0.05). Complete RFP release was observed at 21.5, 17.5 and 14.5 days in VA-DDS, DA-DDS and SA-DDS, respectively (P < 0.05). As the VA-DDS shows highest RFP loading capacity and most sustained drug release, VA is recommended for the construction of porous β-TCP/RFP drug delivery systems.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Rifampin, Tuberculosis, Spinal, Drug Carriers, Tissue Engineering

CLC Number:

R318

Sun Wei, Xue Cheng, Tang Xian-ye, Yuan Feng, Guo Kai-jin, Zhang Dong, Yuan Jun-jie, Xie You-zhuan. The drug loading capacity and controlled drug release property of beta-tricalcium phosphate/rifampicin drug delivery systems constructed by different solution adsorption methods[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(30): 4824-4828.

Figures/Tables 4

References

[1] Kandwal P, G V, Jayaswal A. Management of tuberculous infection of the spine. Asian Spine J. 2016;10(4):792-800.

[2] 孙伟,赵杰,郭开今,等.富集骨髓间充质干细胞用于兔腰椎横突间的融合[J].中国组织工程研究, 2012,16(10):1752-1755.

[3] 费正奇,胡藴玉.抗骨结核缓释药物:载体材料的选择[J].中国组织工程研究, 2015,19(21):3387-3391.

[4] 黄术,张宏其,刘保荣等.新型抗结核缓释体的骨密度初步试验研究[J].中国医师杂志,2014;2:218-220.

[5] Huang D, Li D, Wang T, et al. Isoniazid conjugated poly(lactide-co- glycolide): long-term controlled drug release and tissue regeneration for bone tuberculosis therapy. Biomaterials. 2015;52:417-425.

[6] Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013; 12(11): 991-1003.

[7] Zhang G, Zeng X, Li P. Nanomaterials in cancer-therapy drug delivery system. J Biomed Nanotechnol . 2013; 9(5): 741-750.

[8] Lorenz J, Barbeck M, Kirkpatrick CJ, et al. Injectable bone substitute material on the basis of β-TCP and hyaluronan achieves complete bone regeneration while undergoing nearly complete degradation. Int J Oral Maxillofac Implants. 2018;33(3):636-644.

[9] Sakata M, Tonomura H, Itsuji T, et al. Bone regeneration of osteoporotic vertebral body defects using platelet-rich plasma and gelatin β-tricalcium phosphate sponges. Tissue Eng Part A. 2018;24(11-12):1001-1010.

[10] Liu X, Zhang Y, Xiong K, et al. Fabrication of a novel beta tricalcium phosphate/sodium alginate/poly(D,L-lactic acid) composite microsphere and its drug releasing property. J Nanosci Nanotechnol. 2018;18(6):3844-3849.

[11] 袁君杰,谢幼专.药物缓释载体负载药物方法的研究[J].生命科学, 2013, 25(3): 329-333.

[12] Zhu M, Wang H, Liu J, et al. A mesoporous silica nanoparticulate/ β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy. Biomaterials. 2011;32(7):1986-1995.

[13] Guo YP, Guo LH, Yao YB, et al. Magnetic mesoporous carbonated hydroxyapatite microspheres with hierarchical nanostructure for drug delivery systems. Chem Commun (Camb). 2011; 47(44):12215-12217.

[14] Zhu M, Li K, Zhu Y,et al. 3D-printed hierarchical scaffold for localized isoniazid/rifampin drug delivery and osteoarticular tuberculosistherapy. Acta Biomater. 2015;16:145-155.

[15] Matsushita N, Terai H, Okada T, et al. A new bone-inducing biodegradable porous β-tricalcium phosphate. J Biomed Mater Res A. 2004; 70(3):450-458.

[16] 吕静,叶盛英,王昊,等.负载抗菌药物骨水泥的药物释放实验研究[J].生物骨科材料与临床研究,2017,14(6):7-10.

[17] 毋育伟,陆慧,胡洪成,等.脂联素微球复合 PLGA/β-TCP 支架材料的制备及生物活性评价[J].实用口腔医学杂志, 2015, 31(5):615-618.

[18] Chiang PC, Ran Y, Chou KJ, et al. Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery. AAPS PharmSciTech.2012;13(2):713-722.

[19] Hoang Thi TH, Morel S, Ayouni F, et al. Development and evaluation of taste-masked drug for paediatric medicines-Application to acetaminophen. Int J Pharm.2012; 434(1):235-242.

[20] Swarnakar NK, Jain AK, Singh RP, et al. Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials. 2011; 32(28):6860-6874.

[21] 李昱,张占召,吴鼎宇,等. 包埋载辛伐他汀PLGA微球的胶原/壳聚糖支架的制备及其生物相容性研究[J].组织工程与重建外科杂志, 2017,13(2):61-65.

[22] Zhang Y, Zhang Q, Sun J, et al. The combination therapy of salinomycin and gefitinib using poly(d,l-lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles for targeting both lung cancer stem cells and cancer cells. Onco Targets Ther.2017; 10:5653-5666.

[23] Xiao FJ, Peng L, Zhang Y, et al. Silicon-substituted hydroxyapatite composite coating by using vacuum-plasma spraying and its interaction with human serum albumin. J Mater Sci Mater Med. 2009; 20(8): 1653-1658.

[24] Mandeville JS, Bourassa P, Thomas TJ, et al. Biogenic and synthetic polyamines bind cationic dendrimers. PloS one. 2012; 7(4):e36087.

[25] Barsoum BN, Kamel MS, Diab MM. Spectrophotometric determination of isoniazid and rifampicin from pharmaceutical preparations and biological fluids. Res J Agric Biol Sci. 2008; 4(5):471-484.

[26] Zhang X, Wyss UP, Pichora D, et al. A mechanistic study of antibiotic release from biodegradable poly (d, l-lactide) cylinders. J Control Release. 1994; 31(2):129-144.

[27] Dohzono S, Imai Y, Nakamura H, et al. Successful spinal fusion by E. coli-derived BMP-2-adsorbed porous beta-TCP granules: a pilot study. Clin Orthop Relat Res. 2009; 467(12):3206-3212.

[28] Bemer-Melchior P, Bryskier A, Drugeon HB. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother. 2000; 46(4):571-576.